Leukotriene E4, random urine-994
Test info
Leukotriene E4, random urine
994
LAB994
MSO
Cysteinyl Leukotriene
LTE4
Mast Cell Activation Syndrome
Mastocytosis
Systemic Mast Cell Activation
LTE4
Mast Cell Activation Syndrome
Mastocytosis
Systemic Mast Cell Activation
An aid to evaluate patients suspected of having systemic mastocytosis using random urine collections
Specimen
Urine, random
5 mL
2 mL
- Transfer a 5 mL (minimum 2.0mL) aliquot to a Screw cap transfer vial/tube (Mayo T914), labeled as urine
Frozen (preferred) – 30 days
Refrigerated - 7 days
Ambient - 24 hours
Performance
Mayo Clinic Laboratories (RLTE4): R-NX
Mo, Th
6 days
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Enzymatic Colorimetric Assay
Clinical and Interpretive info
≤104 pg/mg creatinine
Patients taking 5-lipoxygenase inhibitor zileuton/Zyflo may have decreased concentrations of leukotriene E4 (LTE4) if dosage has not been discontinued for 48 hours.
Systemic mastocytosis is a heterogenous disease and lack of elevated LTE4 does not exclude the diagnosis of mast cell disease.
Increased excretion of LTE4 has also been reported in the following conditions: asthma, eosinophilic pneumonia, respiratory syncytial virus infection, atopic dermatitis, Crohn disease, and rheumatoid arthritis.
Systemic mastocytosis is a heterogenous disease and lack of elevated LTE4 does not exclude the diagnosis of mast cell disease.
Increased excretion of LTE4 has also been reported in the following conditions: asthma, eosinophilic pneumonia, respiratory syncytial virus infection, atopic dermatitis, Crohn disease, and rheumatoid arthritis.
Billing
82542
82570
82570
Tracking
03/01/2022
02/06/2023
03/01/2022